cartilage degradation and confirms a link between a native biological pathway and pharmacology which translates to human tissues and non-human primate models, subsequently pointing to a specific OA patient population to target. However, our results suggest selective and potent ADAMTS-5 engagement/inhibition with GSK2394002, while demonstrating desired effects on cartilage-related endpoints, results in modulation of CV functions that pose considerable challenges for clinical development.
test). There were no significant differences in the concentrations of EGF, insulin-like growth factor-1 (IGF-1), and TGF-b in the outputs of the APS and Orthokine device systems. However, the APS Device System produced solutions with significantly greater concentrations of PDGF-AB and PDGF-BB than the Orthokine Device System (p < 0.05, t-test). Conclusions: The APS device system produced solutions with significantly greater concentrations of anti-inflammatory cytokines and similar or greater concentrations of anabolic growth factors than the Orthokine or Onoccomed 2 Device Systems. Significantly, the average IL-1ra concentration in the output of the APS Device system was 34X that of the Orthokine Device System and 198X that of the Onoccomed 2 Device System from the same donors. The cytokine profile of APS can be attributed to its increased concentrations of WBC and platelets compared to the acellular conditioned serums. Table 1 Concentration of white blood cells (WBC) (k/ml), Platelets (k/ml), and red blood cells (RBC) (M/ml) Purpose: Transforming growth factor beta (TGF-b) is an important regulator in determining cell fate of human mesenchymal stem cells (hMSCs), specifically down the chondrogenic lineage. Yet control of this differentiation within a complex in vivo milieu remains a challenge. A localized therapy such as an intra-articular injection of a system for controlled release of TGF-b3 would represent a readily translatable approach for in situ differentiation and remove the need for continuous supplementation of growth factors. Hyaluronan (HA) is an essential component of cartilage extracellular matrix (ECM) and serves as a support for cell adhesion, spreading and subsequently, cell growth. Thus, our aim was to fabricate chondromimetic HA microspheres and test these as extracellular growth factor targeting depots for initiation of in vitro and ex vivo chondrogenesis of hMSCs. Methods: HA microspheres were fabricated using an electrostatic layerby-layer strategy and characterized by scanning electron microscopy. hMSCs isolated from the iliac crest of healthy donors were obtained with approval from the National University of Ireland Galway and associated University College Hospital ethics committees and cultured in a-MEM containing 10% FBS, 100U/ml penicillin and 100mg/ml streptomycin. The effects of microspheres on cell number and metabolic activity were determined using the PicoGreen dsDNAÒ and alamarBlueÔ assays. Confocal microscopy, flow cytometry and transmission electron microscopy were utilized to investigate co-localization of HA microspheres with hMSCs to ensure they were not taken up by cells. Purpose: Articular cartilage has a limited capacity for self-repair and untreated damage often leads to the development of osteoarthritis and eventually joint failure. Currently, autologous chondrocyte implantation is the most successful method for repairing focal cartilage defects. This therapy involves the isolation of chondrocytes from articular cartilage by enzymatic degradation. This not only strips the cells from their extra cellular matrix, but also from their highly specialized microenvironments, called chondrons. This initiates dedifferentiation, i.e. the isolated chondrocytes progressively lose their chondrogenic phenotype, and thus reduces the clinical success of the therapy. We aim to develop a strategy to encapsulate expanded single chondrocytes in artificial chondrons. When successful, this approach represents a cost-effective method to prevent further dedifferentiation, while simultaneously allows for optimal stimulation of the encapsulated chondrocytes. Here, we present a microfluidic device able to encapsulate single chondrocytes in chondron-sized (<50 mm) microgels in a custom designable artificial matrix using an efficient and cell-friendly manner. Methods: The master mould for the optimized microfluidic droplet generator was made by micropatterning w25 mm thick SU8-50 (MicroChem) on a silicon wafer using standard photolithography techniques. PDMS (Sylgard 184, Dow Corning) was thermally cured on the master and bonded to glass after plasma treatment. Aquapel (Vulcavite) was introduced in the chip before usage to ensure hydrophobic channels walls. We compared various combinations of oils, surfactants, photoinitiators and UV dosages, as these are of paramount importance to obtain chondron-sized microgels. Chondron-sized droplets were produced by emulsifying a chondrocyte-laden hydrogel precursor solution of 10% (w/v) polyethylene glycol diacrylate (PEGDA, Laysan Bio, Inc.) and 0.1% (w/v) photoinitiator (Irgacure 2959, Ciba Specialty Chemicals) in hexadecane (Sigma) with 1% Span80 (Sigma). Subsequently, the microgels were formed in an on-chip delay channel by curing the emulsion with 365nm UV-light (Hamamatsu LC8).
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Results: Chondrocytes were encapsulated in PEGDA microgels using droplet microfluidics at a rate of typically 20,000 cells per minute. The number of encapsulated cells followed a Poisson-distribution that was dependent on the cell concentration. We aimed to minimize the microgels' dimensions by comparing different combinations of oils, surfactants and UV dosages. Fluorinated oils in combination with PEGylated fluorosurfactants resulted in the most stable emulsions and thus allowed for the lowest photoinitiator concentration and UV dose for cell-laden microgel production. However, the use of fluorinated oils resulted in relatively large gels, which is a consequence of their low viscosity compared to the hydrogel precursor solution. In contrast, the use of a more viscous hydrocarbon oil with Span80 surfactant resulted in smaller, chondron-sized microgels. However, emulsions with this oil/ surfactant combination were less stable off-chip. Solid on-chip crosslinking was accomplished by using an extended delay channel which enabled prolonged UV radiation without compromising the production rate. Finally, by varying the flow rates of the continuous and dispersed 
